| Literature DB >> 32213567 |
Nessrine Bellamri1, Roselyne Viel2, Claudie Morzadec1, Valérie Lecureur1, Audrey Joannes1, Bertrand de Latour3, Francisco Llamas-Gutierrez4, Lutz Wollin5, Stéphane Jouneau6,7, Laurent Vernhet8.
Abstract
The chemokine CXCL13 controls the normal organization of secondary lymphoid tissues and the neogenesis of ectopic lymphoid structures in nonlymphoid organs, particularly the lungs. The progression and severity of idiopathic pulmonary fibrosis (IPF), a fatal and irreversible interstitial lung disease, is predicted by the circulating blood concentrations of CXCL13. Although CXCL13 is produced by pulmonary tissues, it has not been determined which cells are involved. This study examines CXCL13 production by lung tissue macrophages from patients with IPF and the signaling pathways controlling CXCL13 gene expression in human alveolar macrophages (AM) and monocyte-derived macrophages (MoDM). CXCL13 is found in CD68- and CD206-positive AM from patients with IPF, and the CXCL13 gene is induced in these macrophages and MoDM when they are stimulated with LPS. We found that TNF-α and IL-10 control optimal CXCL13 gene expression in MoDM and possibly in AM by activating the NF-κB and JAK/STAT pathways, respectively. We also found that blood TNF-α and CXCL13 concentrations are significantly correlated in patients with IPF, suggesting that TNF-α contributes to CXCL13 production in humans. In conclusion, the results of this study demonstrate that AM from patients with IPF produces CXCL13 and that the NF-κB and JAK/STAT pathways are required to induce the expression of this major chemokine.Entities:
Year: 2020 PMID: 32213567 DOI: 10.4049/jimmunol.1900790
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422